Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888257 | 0.97 | HPGDS (0.31) | CHEK2GPR119DGAT1TSHRMEN1 | |
| SCHEMBL12661193 | 0.94 | CHEK2 (0.34) | CHEK2GPR119DGAT1TSHRMEN1 | |
| SCHEMBL933689 | 0.91 | HPGDS (0.33) | CHEK2GPR119DGAT1TSHRMEN1 | |
| SCHEMBL1889043 | 0.89 | DGAT1 (0.34) | CHEK2GPR119DGAT1TSHRMEN1 | |
| SCHEMBL1892009 | 0.89 | CHEK2 (0.34) | CHEK2GPR119DGAT1TSHRMEN1 | |
| SCHEMBL12661154 | 0.88 | CHEK2 (0.34) | CHEK2GPR119DGAT1TSHRMEN1 | |
| SCHEMBL933373 | 0.87 | CHEK2 (0.30) | CHEK2 | |
| SCHEMBL933407 | 0.87 | DGAT1 (0.32) | CHEK2GPR119DGAT1TSHRMEN1 | |
| SCHEMBL932641 | 0.86 | HPGDS (0.33) | CHEK2GPR119TSHRMEN1LMNA | |
| SCHEMBL932995 | 0.86 | GPR119 (0.33) | CHEK2GPR119DGAT1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | CHEK2 3724/4885GPR119 2249/4885DGAT1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.